Phuturdex › Diseases › Cutaneous T cell lymphoma
Drugs in development · updated 30 October 2026
Cutaneous T cell lymphoma: drugs in development
As of 30 October 2026 there are 38 active clinical trials (recruiting or ongoing, phases I–III) on 46 drugs for cutaneous T cell lymphoma. 15 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Golidocitinib | I–II | 2 | NCT07754890 |
| Aclarubicin | I–II | 1 | NCT07535710 |
| ChidamideTucidinostat, HBI-8000 | I–II | 1 | NCT07754890 |
| MDSY-1240 | I–II | 1 | NCT07899632 |
| PTX-100 | II | 1 | NCT06854653 |
| Zeprumetostat | II | 1 | NCT07854639 |
| BITR2101 | I | 1 | NCT06385522 |
| CHT101 | I | 1 | NCT06914037 |
| DS-3201b | I | 1 | NCT02732275 |
| Fenretinide | I | 1 | NCT04234048 |
| INCA036873 | I | 1 | NCT07195916 |
| KK2223 | I | 1 | NCT07192471 |
| Sodium-Iodide Symporter | I | 1 | NCT03017820 |
| TLN-254 | I | 1 | NCT06733441 |
| DT-7012 | Early I | 1 | NCT07213882 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Brentuximab VedotinSGN-35, Adcetris® | III | 3 | NCT07178457 |
| MogamulizumabPoteligeo® | II | 5 | NCT04930653 |
| CyclophosphamideCyclophosphamid, Cytoxan | I–II | 4 | NCT07535710 |
| PembrolizumabKEYTRUDA, MK-3475 | II | 4 | NCT05313243 |
| FludarabineFludara, FLUDARABIN | II | 3 | NCT00544115 |
| RuxolitinibJakavi, Jakafi Xr® | II | 3 | NCT07356245 |
| NivolumabOpdivo, ONO-4538 | II | 2 | NCT02978625 |
| BusulfanBusulphan, Busulfex® | II | 1 | NCT00544115 |
| CyclosporineCyclosporine A, Cyclosporin Capsules | II | 1 | NCT00544115 |
| DelgocitinibAnzupgo® | II | 1 | NCT07781449 |
| DurvalumabMEDI4736, Imfinzi® | I–II | 1 | NCT03011814 |
| EtoposideAvopef®, Etopophos Preservative Free® | II | 1 | NCT00544115 |
| LenalidomideRevlimid, lenalinomide | I–II | 1 | NCT03011814 |
| MelphalanEvomela®, Hepzato® | II | 1 | NCT00544115 |
| MethotrexateJylamvo®, Reditrex® | II | 1 | NCT00544115 |
Sorted by most advanced phase and number of active trials. Showing 15 of 31 drugs.
All 46 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Mycosis fungoides 40 drugs
- Sezary Syndrome 30 drugs
- Anaplastic large-cell lymphoma 36 drugs
- T-cell lymphoma 74 drugs
- Immunoblastic lymphadenopathy 32 drugs
- Peripheral T-cell lymphoma 71 drugs
- Enteropathy-associated T-cell lymphoma 13 drugs
- Follicular lymphoma 144 drugs
- Subcutaneous T-cell lymphoma 5 drugs
- Lymphomatoid papulosis 3 drugs
- Breast neoplasm 593 drugs
- Sarcoma 204 drugs
Broader categories
- Lymphoproliferative disorders 51 drugs
- Lymphatic system disease 20 drugs
- Immunoproliferative disorder 16 drugs
- Neoplasm 671 drugs
- Immune System Diseases 54 drugs
- Non-Hodgkin lymphoma 269 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D016410 “Lymphoma, T-Cell, Cutaneous”. Prevalence: Orphanet.